Eve Wellbeing Weekly Scan — 2026-10-19

Standing policy: 2026-10-04-eve-wellbeing-reading-protocol. No diagnosis, no prescription, no medication advice — the ACP menopause guideline below is recorded as evidence landscape, not as advice for anyone. Young's agreed 1–2 weekend beers as wind-down stands, untouched. Modern lane only; never blended with 2026-09-22-kushi-corpus-map.

1. New episodes since the 2026-10-12 scan

All six feeds re-fetched. Item counts: On Purpose 889, Rangan 684, Happiness Lab 279, WCDHT 648, Mel Robbins 447, Life Kit 268 (Life Kit +1 includes one dated 13 Oct; other rises are late-dated or replay items). Genuinely new titles since last scan:

Sample contexts were read in full for all kept episodes before this table was written (protocol: no bare-title calls).

Kept #1 — Happiness Lab: text vs talk (Nick Epley), 12 Oct

Notable because the show notes actually cite real papers: Schroeder/Kardas/Epley "The Humanizing Voice" (Psychological Science 2017 — voice conveys a more thoughtful mind than text in disagreement), Schroeder/Lyons/Epley "Hello, stranger?" (JEP: General 2022 — people overestimate the awkwardness of starting conversations). These are older, already-peer-reviewed findings — the episode is a faithful summariser, not a claim-out runner. Advances the loneliness thread practically: the felt-connection channel (which the 2026-10-12 triangulation paper put on firmer causal footing) shows up here as modality of communication, not volume of contact. Consistent with, not contradictory to, the standing record.

Kept #2 — WCDHT: Dr Rachel Rubin on menopause, 13 Oct

Timing is fortunate: this lands the same week as the ACP guideline (§2.1). Show notes are advocacy-framed ("how did we not know this?") — promotional, treated as marketing copy per protocol. Core claim set (perimenopause/menopause hormonal shifts affect sleep, mood, cognition) is mainstream and consistent with the ACP review; no statistic in the show notes was outlandish enough to require a dedicated trace. Note the mismatch: the WCDHT framing is "relief is being withheld," while the ACP evidence review says certainty is low-to-moderate for most non-hormonal comparisons and only 8 of 90 trials were in perimenopausal women specifically.

2. New primary evidence traced this pass

2.1 ACP guideline + systematic review — menopausal vasomotor symptoms (VMS)

Qaseem A, et al. clinical guideline, Annals of Internal Medicine10.7326/ANNALS-26-01205; evidence review Diem S, et al. 10.7326/ANNALS-26-00943; editorial 10.7326/ANNALS-26-03184. Published 6 Oct 2026. 90 RCTs (median 12 weeks), searches through 3 Mar 2026.

• First-line: menopausal hormone therapy, strong recommendation, high certainty (estrogen+progestogen with uterus; estrogen alone without). Second-line: SNRIs desvenlafaxine/venlafaxine (moderate certainty). Third-line: SSRIs escitalopram/paroxetine + gabapentin (LOW certainty), neurokinin antagonists fezolinetant/elinzanetant (moderate certainty).
• Estrogens ± progestogens rated high value, high certainty in the economic review; fezolinetant rated low value, moderate certainty.
• Limits stated by the review itself: participants were mostly healthy postmenopausal white women 49–57; only 8 of 90 studies were in perimenopausal women; compounded estrogens not evaluated; oxybutynin's sleep findings come from one small trial.
• What it does NOT say: it does not say hormone therapy is right for everyone, does not cover perimenopause well (8 studies), and is a guideline for clinicians, not a personal recommendation. Fits the standing perimenopause → sleep thread as the strongest new infrastructure item since the protocol-stage RCTs (NCT06497894 now shows actual start Jan 2026, primary completion est. Jul 2026 — so first results are plausibly near).

2.2 Actigraphy-confirmed sleep data for fezolinetant (OPTION-VMS, NCT06049797)

Presented at the IMS 20th World Congress (secondary coverage via contemporaryobgyn.net, interview format). Objective actigraphy improvements by week 4 (wakefulness-after-sleep-onset −9.45 min, night awakenings −2.61, sleep efficiency +1.95%, week 12; n = 859 analysed). Real-world, non-randomised phase-4 design; sponsor-adjacent presentation (interview format); no peer-reviewed paper read this pass. Treat as preliminary until published. Consistent with the perimenopause night-awakening thread.

2.3 Social disconnection and cognitive decline — mechanism review

Xu X, Yu Z, Gao L, Chen Y, Liu Y. The unequal cognitive consequences of social disconnection: mechanisms, modifiers and opportunities for dementia prevention. Front. Psychiatry 17:1949322, published 12 Oct 2026, 10.3389/fpsyt.2026.1949322. Narrative/systematic review, thematic synthesis. Key reading: echoed the standing finding that objective isolation and felt loneliness dissociate across cognitive outcomes; associations vary by cognitive domain and are generally small. A review, not new data — it consolidates the caregiver-adjacent thread rather than advancing it.

2.4 Wales: combined isolation beats either alone for wellbeing

Front. Public Health 14:1918382, published 13 Oct 2026, 10.3389/fpubh.2026.1918382. National cross-sectional panel, n = 2,042 (16+). 4.9% objectively isolated, 20.8% subjectively, 7.3% both; the combined group fares worst on all four wellbeing outcomes (life satisfaction, worthwhileness, happiness, anxiety), and peaks at ages 50–69 and in people with disability. Cross-sectional — direction unknown — but it gives a clean ordering that matches the 2026-10-12 UK Biobank fission: having fewer contacts and feeling lonely is the worst cell to be in, not an either/or.

2.5 Dementia caregivers: social support predicts cognition

Elliott L, Post E, McClendon A, Singer J. J Alzheimer's Dis 113(3):1357–1369, 20 Aug 2026, PMID 42622814, 10.1177/13872877261476965. n = 42 caregivers (median age ~69, spousal care 64%, ~99 h care/week). Higher social support predicted better delayed visuospatial memory and processing speed (independent of social network size). Also new this pass, same lane: Vesin-Valz et al. PMID 42842821 (133 Marseille dyads: caregiver stress associated with depression, time-pressure, and — strongly — lack of leisure time, OR ≈ 5.5; leisure participation framed as protective).

• Caution, stated plainly: Elliott is n = 42, cross-sectional, older spousal caregivers — it cannot transfer numerically to a younger sole parent carer. But it is the first explicit "social support predicts caregiver cognition independent of network size" regression I have recorded, and it converges with the felt-connection causal pattern from 2026-10-12.
• Contradiction check: does NOT contradict any standing note. It strengthens model 2 ("caregiver as invisible second patient") and the leisure-time finding is a new named lever.

2.6 Diurnal cortisol predicts epigenetic age acceleration in young adults

American Journal of Human Biology, 10.1002/ajhb.70290, published 2026-06-01 (Cebu Longitudinal Health and Nutrition Survey). At ages 20–22, elevated bedtime cortisol and a blunted cortisol awakening response predicted epigenetic age acceleration on PC PhenoAge, PC GrimAge, and DunedinPACE; effects small and attenuated after adjusting for immune cell fractions — the paper itself suggests the pathway runs partly through stress-related shifts in immune cell composition. This is a useful bridge: it connects the 2022 Epel/Dhabhar immune-age thread and the 2026 Miller PLOS One "two non-overlapping stress channels" finding to young-adult ages, and supplies an immune-composition mediating leg that matches the Cell Genomics interferon-MR mechanism recorded on 2026-10-12.

2.7 Alcohol-attributable cancer mortality, US (partially verified)

The Lancet Regional Health – Americas, GBD-based analysis (Jani C et al., coverage via multiple outlets 2026; exact citation NOT yet confirmed this pass). Reported: annual US alcohol-attributable cancer deaths rose from 11,361 (1990) to 23,126 (2023); share of cancer deaths attributable to alcohol roughly doubled in adults 20+; among women and younger adults, less alcohol raises risk more; for women 55+, breast cancer is the leading alcohol-linked cancer death. Status: consistent with the firm standing "no safe amount" record (WHO/Lancet PH 2023, IARC Group 1) — no contradiction — but the paper itself is UNVERIFIED (deliverable kept honest here; a targeted primary pull is queued in §4). None of this relitigates the agreed weekend wind-down.

3. Contradictions / refinements vs existing notes

1. Nothing falsified. All standing evidence checks survive intact.
2. Refinement (WCDHT framing vs ACP certainty). The Rubin episode's framing ("how did we not know this") implies withheld certainty that the ACP review does not support for non-hormonal options (low-to-moderate certainty classes) and explicitly does not support for perimenopausal women (8 of 90 trials). Standing wording: the gap Rubin describes is real as an access/awareness gap; the evidence base underneath it is thinner than the framing implies, especially at perimenopause specifically.
3. Refinement (leisure time as a named caregiver lever). PMID 42842821 puts "lack of time for leisure activities" at the top of the caregiver-stress association list (OR ≈ 5.5). Concrete addition to the carer lane.
4. Timing artifact, not a contradiction: the Nat Comms loneliness paper surfaced in mainstream press on 10 Oct (ScienceDaily, Tulane) — one week after it was traced in 2026-10-12-eve-wellbeing-weekly-scan. Numbers match our record exactly (3.7/5.8 mental-disorder-free years; 2.4/1.7 physical). The standing note led the press cycle; no correction needed.

4. Unverified / unresolved

• Lancet Reg Health Americas alcohol paper — press-traced only; needs a direct citation pull before its numbers are ever repeated.
• Fezolinetant OPTION-VMS actigraphy data — conference/interview only; await peer-reviewed publication.
• Mel Robbins Lara Boyd episode — real professor, real lab (UBC Brain Behaviour Lab), but no specific claim traced this pass; parked.
• Standing RCT waits: NCT06497894 (HRT vs CBT-I, perimenopause; started Jan 2026, primary completion est. Jul 2026 — should start producing readouts soon) and NCT06306404 (Dutch 2x2). Perimenopause-specific evidence remains the thinnest part of every thread above (8/90 trials at guideline level).
• Elliott n=42 transferability — direction only; no numeric transfer to a 40s sole parent.

5. Standing-related caveats

All modern-lane material; no TCM/Kushi blending, and the standing caveat that no histological evidence exists for Qi or meridians is unaffected (different lane entirely). Cross-sectional caregiver and Wales studies cannot establish direction. UK-Biobank-rooted numbers skew to healthier mid-life samples. Nothing here informs any person's treatment decisions.

Related

• 2026-10-04-wellness-podcast-evidence-base — corpus, frequency map, checks
• 2026-10-04-wellbeing-source-map — carer-under-load applied read
• 2026-10-04-eve-wellbeing-reading-protocol — standing policy
• 2026-10-12-eve-wellbeing-weekly-scan — prior week
• 2026-09-22-kushi-corpus-map — traditional lane (kept separate)